Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits

被引:57
作者
Goldsmith, David R. [1 ]
Rapaport, Mark Hyman [1 ]
机构
[1] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA
来源
FRONTIERS IN PSYCHIATRY | 2020年 / 11卷
关键词
inflammation; cytokines; negative symptoms; reward; motivation; schizophrenia; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TREATMENT-RESISTANT SCHIZOPHRENIA; DOPAMINE SYNTHESIS CAPACITY; NUCLEUS-ACCUMBENS DOPAMINE; DECISION-MAKING PARADIGMS; CONTINUOUSLY ILL PATIENTS; RESEARCH DOMAIN CRITERIA; C-REACTIVE PROTEIN; FUNCTIONAL CONNECTIVITY; DIMINISHED EXPRESSION;
D O I
10.3389/fpsyt.2020.00046
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Negative symptoms of schizophrenia are debilitating and chronic in nature, are difficult to treat, and contribute to poor functional outcomes. Motivational deficits are a core negative symptom and may involve alterations in reward processing, which involve subcortical regions such as the basal ganglia. More specifically, dopamine-rich regions like the ventral striatum, have been implicated in these reward-processing deficits. Inflammation is one mechanism that may underlie negative symptoms, and specifically motivational deficits, via the effects of inflammatory cytokines on the basal ganglia. Previous work has demonstrated that inflammatory stimuli decrease neural activity in the ventral striatum and decrease connectivity in reward-relevant neural circuitry. The immune system has been shown to be involved in the pathophysiology of schizophrenia, and inflammatory cytokines have been shown to be altered in patients with the disorder. This paper reviews the literature on associations between inflammatory markers and negative symptoms of schizophrenia as well as the role of anti-inflammatory drugs to target negative symptoms. We also review the literature on the role of inflammation and reward processing deficits in both healthy controls and individuals with depression. We use the literature on inflammation and depression as a basis for a model that explores potential mechanisms responsible for inflammation modulating certain aspects of negative symptoms in patients with schizophrenia. This approach may offer novel targets to treat these symptoms of the disorder that are significant barriers to functional recovery and do not respond well to available antipsychotic medications.
引用
收藏
页数:14
相关论文
共 186 条
  • [1] Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis
    Addington, Jean
    Shah, Hely
    Liu, Lu
    Addington, Donald
    [J]. SCHIZOPHRENIA RESEARCH, 2014, 153 (1-3) : 64 - 67
  • [2] Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia
    an der Heiden, Wolfram
    Leber, Anne
    Haefner, Heinz
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2016, 266 (05) : 387 - 396
  • [3] Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci
    Andreassen, O. A.
    Harbo, H. F.
    Wang, Y.
    Thompson, W. K.
    Schork, A. J.
    Mattingsdal, M.
    Zuber, V.
    Bettella, F.
    Ripke, S.
    Kelsoe, J. R.
    Kendler, K. S.
    O'Donovan, M. C.
    Sklar, P.
    McEvoy, L. K.
    Desikan, R. S.
    Lie, B. A.
    Djurovic, S.
    Dale, A. M.
    [J]. MOLECULAR PSYCHIATRY, 2015, 20 (02) : 207 - 214
  • [4] Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia
    Asevedo, Elson
    Rizzo, Lucas B.
    Gadelha, Ary
    Mansur, Rodrigo B.
    Ota, Vanessa K.
    Berberian, Arthur A.
    Scarpato, Bruno S.
    Teixeira, Antonio L.
    Bressan, Rodrigo A.
    Brietzke, Elisa
    [J]. PHYSIOLOGY & BEHAVIOR, 2014, 129 : 194 - 198
  • [5] Barch DM, 2016, CURR TOP BEHAV NEURO, V27, P411, DOI 10.1007/7854_2015_376
  • [6] Effort, Anhedonia, and Function in Schizophrenia: Reduced Effort Allocation Predicts Amotivation and Functional Impairment
    Barch, Deanna M.
    Treadway, Michael T.
    Schoen, Nathan
    [J]. JOURNAL OF ABNORMAL PSYCHOLOGY, 2014, 123 (02) : 387 - 397
  • [7] Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-Year Population-Based Register Study
    Benros, Michael E.
    Nielsen, Philip R.
    Nordentoft, Merete
    Eaton, William W.
    Dalton, Susanne O.
    Mortensen, Preben B.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2011, 168 (12) : 1303 - 1310
  • [8] The structure of negative symptoms within schizophrenia: Implications for assessment
    Blanchard, JJ
    Cohen, AS
    [J]. SCHIZOPHRENIA BULLETIN, 2006, 32 (02) : 238 - 245
  • [9] Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study
    Bobes, Julio
    Arango, Celso
    Garcia-Garcia, Margarida
    Rejas, Javier
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (03) : 280 - 286
  • [10] C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia
    Boozalis, Ted
    Teixeira, Antonio L.
    Cho, Raymond Young-Jin
    Okusaga, Olaoluwa
    [J]. FRONTIERS IN PUBLIC HEALTH, 2018, 5